Articles

Rallybio Pursues Reverse Merger with Avenzo Therapeutics to Advance Autoimmune Pipeline

Rallybio is attempting a reverse merger with Avenzo Therapeutics, a move that will see the combined entity focus on Avenzo's T-cell engager pipeline for autoimmune diseases. The transaction includes a substantial concurrent financing round.

Navigating Demands for Unvaccinated Donor Blood: A Hospital's Ethical and Operational Challenge

Patients increasingly demand blood from unvaccinated donors, creating ethical dilemmas and operational hurdles for hospitals. This trend raises critical questions about patient safety, resource allocation, and the integrity of blood supply.

Medicare's GLP-1 Stance and UnitedHealthcare Lawsuit: Key Implications for Pharma

Medicare's silence on GLP-1 coverage for obesity and Massachusetts' lawsuit against UnitedHealthcare present significant challenges and opportunities for the pharmaceutical industry. This article breaks down the key developments and their strategic impact.

ASCO 2026: Grief Takes Center Stage Amidst Cancer Data

The American Society of Clinical Oncology (ASCO) 2026 meeting saw a notable shift, with the emotional weight of cancer care and grief taking precedence over data readouts. This focus highlights a critical, often overlooked, aspect of oncology practice.

Obefazimod ABTECT: UC Remission vs Safety Watch

Abivax's obefazimod has demonstrated significant efficacy in ulcerative colitis trials, generating excitement for potential regulatory approval. However, recent reports of cancer cases necessitate a careful evaluation of its safety profile by investors and business development teams.

Merck's ADC Success: Insights from Global Trial Results

This article delves into Merck's successful antibody-drug conjugates (ADCs) and their global trial results, highlighting key insights for investors and BD teams.

UCB's Bimzelx Triumphs Over AbbVie's Skyrizi in Psoriatic Arthritis

UCB's Bimzelx has shown superior efficacy compared to AbbVie's Skyrizi in treating psoriatic arthritis, marking a significant milestone in the competitive landscape. This article analyzes the implications for pharmaceutical business development teams.

Niowave's $75M Radiopharmaceutical Plant: Industry Implications

Niowave has initiated construction on a $75 million radiopharmaceutical plant in Michigan, marking a significant investment in Actinium-225 production. This development has far-reaching implications for the pharmaceutical industry and investment strategies.

FDA Leadership Changes: Implications for the Pharmaceutical Industry

This article analyzes the recent leadership changes at the FDA and their potential impact on the pharmaceutical industry, focusing on business development and regulatory strategies.

How to Use openFDA and FAERS Data Without Misreading Safety Signals

This article provides insights on effectively using openFDA and FAERS data while avoiding common pitfalls in interpreting safety signals. It is essential for analysts and business development teams in the pharmaceutical industry.

Tech Initiatives at Summa Health Post-General Catalyst Acquisition

This article discusses the technology initiatives at Summa Health following its acquisition by General Catalyst, highlighting key insights for B2B readers.

Orphan Drugs 2026: FDA Incentives, IRA Rules

The 2026 Orphan Drugs Report highlights critical trends and challenges in the orphan drug landscape, offering insights for pharmaceutical stakeholders.

Ivonescimab HARMONi-6 Lung Cancer Survival

Akeso and Summit's recent lung cancer trial results indicate significant survival benefits. This article explores the implications for the pharmaceutical industry.

RevMed ASCO Win vs Ivonescimab Caution

RevMed receives accolades for its recent advancements while Akeso faces scrutiny. This article dissects the implications for the pharmaceutical industry.

Daraxonrasib Pancreatic Cancer Phase 3 Results

Revolution Medicines has reported groundbreaking results for its pancreatic cancer drug, potentially transforming treatment protocols. This article explores the implications for the pharmaceutical industry.

Ultra-Low-Dose Nivolumab Cancer Access

Ultra-low doses of cancer treatments could significantly improve accessibility for patients in low-income regions. This article discusses recent developments and implications for the pharmaceutical industry.

Weight Loss Drugs: FDA Regulatory Updates

This article tracks the latest regulatory updates on 14 new weight loss drugs, focusing on implications for pharmaceutical teams and investors. Key insights on FDA processes included.

Commissioner's National Priority Voucher Pilot Program: Clinical Trials Insights

This article analyzes the CNPV Pilot Program's implications for clinical trials and investment strategies in the pharmaceutical sector.

Tracking Biotech FDA Decisions in 2026

This article analyzes biotech stocks awaiting FDA decisions in June 2026, highlighting investment implications and competitive impacts.

Upcoming BIO 2026: Key Insights for B2B Readers

BIO 2026 is set to take place in San Diego from June 22-25, 2026. This event will showcase pivotal advancements in biotechnology and pharmaceutical sectors.